SUBMIT AN ABSTRACT

Abstracts are currently invited for oral or poster presentations at the conference. Authors should submit abstracts **via e-mail** to the following address **sobrevia@med.puc.cl** by **September 14th, 2005**, for publication in one of the following international journals: **PLACENTA** or **BIOLOGICAL RESEARCH.**

All abstracts should be in **WORD format** sent as an attachment (please, **do not embed** your abstract into the e-mail body text).

Please indicate in your e-mail (**NOT** in your word document with your abstract) whether you prefer **Oral communication** or **Poster communication**. The Scientific Committee will decide the final modality for the presentation of your abstract. Invited speakers should indicate whether that abstract they are submitting is for a **Plenary lecture** or a **Symposium seminar**.

All abstracts submitted by the deadline will be, in first instance, refereed by a local committee from II SLIMP Chile 2005 and Sociedad Chilena de Ciencias Fisiológicas (SCHCF). Authors will be communicated within 10 days of submission whether their abstracts were accepted for presentation at the conference. Abstracts that need revision by the authors to comply with editorial guidelines and format from **PLACENTA** or **BIOLOGICAL RESEARCH** will be sent back to authors to address all editorial requests in a maximal period of 5 days. All abstracts that answer editorial requests will be then refereed by an international editorial board from PLACENTA or BIOLOGICAL RESEARCH.

Abstracts submitted after the deadline September 5, may be considered for presentation at the conference but will not be published in PLACENTA or BIOLOGICAL RESEARCH.

Abstracts related to placenta studies will be eligible for publication in PLACENTA. Other topics will be eligible for publication in BIOLOGICAL RESEARCH.

A criterion of rejection will be lack of originality.

A condition of submission is that, if accepted, the paper will be presented at the Joint meeting of II SLIMP Chile 2005 with the XIX Annual Meeting of Sociedad Chilena de Ciencias Fisiológicas (SCHCF) by a **registered author.**

Each author could submit one abstract free of charge. Submission of a second or more abstracts will be charged CLP 10.000 (or USD 15,70) per additional abstract.

Each author could submit as many abstracts as required.

Successfully submitted abstracts will be acknowledged with an electronic receipt including an abstract reference number, which should be quoted in all correspondence. Allow at least 2 days for your receipt to be returned to you.

For revisions or queries regarding abstracts already submitted

If you do not receive acknowledgement for your abstract submission or you wish to make any essential revisions to an abstract already submitted, please **DO NOT RESUBMIT** your abstract, as this may lead to duplication. Please contact us with details of any revisions or queries. Please quote your reference number.

SPECIFIC GUIDELINES FOR SUBMITTING AN ABSTRACT

(Please strictly follow the instructions below since abstracts should comply requirements from PLACENTA and BIOLOGICAL RESEARCH editorials. Abstracts that do not follow these instructions will not be considered for publication).

TITLE IN CAPITAL LETTERS AND BOLD
Initial. Surname. Institution. Postal address.

Abstract body text should be maximum 1700 characters (including spaces), Font Times New Roman 12. Abstract body text should be in English, using Word format, and including introduction and aim (without heading), and the following subsections **Methods**, **Results**, **Conclusions**. Support source should be included at the end of the abstract body.

Example:

EXPRESSION OF EQUILIBRATIVE NUCLEOSIDE TRANSPORTERS 1 IS MODULATED BY HYPOXIA IN HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS.

[a]A.J. Torres, [a]I. Aedo, [a,b]F. Sanhueza, [a]M. González. [a]Department of Obstetrics and Gynaecology, School of Medicine, Pontificia Universidad Católica de Chile, P.O. Box 114-D, Santiago, Chile. [b]Faculty of Pharmacy, Universidad de Concepción, Chile.

Nucleoside release is increased under conditions of reduced oxygen (O_2) level. Removal of this nucleoside from the extracellular space is mediated by human equilibrative membrane transporters 1 (hENT1) in human umbilical vein endothelial cells (HUVEC). The aim of this research was to determine whether changes in the level of O_2 alter expression and activity of hENT1 in primary cultures of HUVEC. **Methods**: Primary cultures of HUVEC from normal, full term pregnancies were cultured for different periods of time (0-24 h) under different levels of O_2 (21-1%). [^{3}H]Adenosine transport (4 µCi/ml, 20 s, 37°C) was determined for adenosine 15-500 µM in absence or presence of 100 nM nitrobenzylthioinosine (NBMPR), an inhibitor of equilibrative adenosine transport. hENT1 mRNA was quantified by real time RT-PCR, using 28S mRNA as housekeeping gene. Protein level was determined by western blot. **Results**: hENT1 mRNA expression was reduced by hypoxia, an effect that was time dependent (half-maximal effect = 3 ± 1 h). hENT1 protein was also reduced by hypoxia. Maximal transport capacity (V_{max}/K_m) for the NBMPR-sensitive, saturable adenosine transport was lower in 2% O_2 compared with 10% O_2 (physiological O_2 in human umbilical vein), 15% O_2 or 21% O_2. **Conclusions**: Our results suggest that *hENT1* gene expression is down-regulated by hypoxia, an effect that could lead to reduced hENT1 protein level and adenosine transport by HUVEC. Supported by FONDECYT 1030781 & 1030607 (Chile).